Daunorubicin (generic), DaunoXome Newswire

Daunorubicin (generic), DaunoXome Newswire

Comprehensive Real-Time News Feed for Daunorubicin (generic), DaunoXome.

Results 1 - 20 of 50 in Daunorubicin (generic), DaunoXome

  1. Nanoparticles Transforming Future of Novel Drug Delivery Systems (NDDS) in Cancer Therapy MarketRead the original story w/Photo

    Monday Feb 6 | SBWire

    Novel drug delivery systems in cancer therapy comprises technologies such as liquid embolics, nanoparticles, and embolization devices that offer unique ways to cure cancer. In recent years, there has been increasing incidence of various types of cancer across the globe.

    Comment?

  2. Prediction of doxorubicin sensitivity in breast tumors based on gene...Read the original story

    Jan 17, 2017 | CiteULike

    Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Up to date clinical tests for predicting cancer chemotherapy response are not available and individual markers have shown little predictive value.

    Comment?

  3. New clinical study for children with AML aims to kill leukemia cells and minimize cardiac damageRead the original story w/Photo

    Dec 17, 2016 | Medical News

    Imagine conquering childhood cancer, only to find out that years down the road your heart may fail. Unfortunately, many children who have battled cancer face this reality.

    Comment?

  4. New Trial Hopes to Increase Survival for Kids With Cancer, Reduce Risk of Long Term Cardiac DamageRead the original story

    Dec 16, 2016 | Newswise

    Imagine conquering childhood cancer, only to find out that years down the road your heart may fail. Unfortunately, many children who have battled cancer face this reality.

    Comment?

  5. CPX-351 improves survival following allogeneic hematopoietic cell...Read the original story w/Photo

    Dec 5, 2016 | PhysOrg Weblog

    Acute myeloid leukemia, or AML, is a type of cancer of the blood and bone marrow. It occurs most often in older populations and progresses rapidly, interfering with the production of red blood cells, white blood cells and platelets.

    Comment?

  6. CPX-351 improves survival following allogeneic hematopoietic cell...Read the original story w/Photo

    Dec 2, 2016 | EurekAlert!

    Acute myeloid leukemia, or AML, is a type of cancer of the blood and bone marrow. It occurs most often in older populations and progresses rapidly, interfering with the production of red blood cells, white blood cells and platelets.

    Comment?

  7. Jazz Pharma To Present New Data At The Annual American Society of Hematology MeetingRead the original story

    Nov 27, 2016 | BioSpace

    Eleven Presentations Evaluating Marketed and Investigational Compounds for Hepatic Veno-Occlusive Disease and Acute Myeloid Leukemia Presentations Include a Sub-Analysis of Phase 3 Data for Vyxeos , an investigational product for the treatment of AML Patients /PRNewswire/ -- Jazz Pharmaceuticals plc announced today that eleven abstracts, including four oral presentations, supporting the company's hematology and oncology portfolio will be presented at the 58th American Society of Hematology Annual Meeting and Exposition in "The data presentations at ASH reflect our efforts in advancing our diversified pipeline of programs in hematology and oncology, including rare blood disorders such as acute lymphoblastic leukemia and AML, and in complications of hematopoietic stem-cell transplantation such as hepatic VOD," said , M.D., Ph.D., global head of research and development and chief medical ... (more)

    Comment?

  8. A phase I dose-escalation study of PEP02 (irinotecan liposome...Read the original story w/Photo

    Nov 20, 2016 | BioMed Central

    PEP02 is a novel nanoparticle formulation of irinotecan encapsulated in liposomes. The aims of this study were to investigate the dose-limiting toxicity , maximum tolerated dose and pharmacokinetics of PEP02 in combination with 5-FU and LV, in patients with advanced refractory solid tumors.

    Comment?

  9. Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos...Read the original story w/Photo

    Oct 2, 2016 | Drugs.com

    Jazz Pharmaceuticals plc today announced the initiation of a rolling submission of a New Drug Application to the United States Food and Drug Administration on September 30, 2016, seeking marketing approval of Vyxeosa , an investigational agent for the treatment of acute myeloid leukemia . The company expects to complete the submission of the NDA by early 2017, and will request a priority review.

    Comment?

  10. A comparison of clofarabine with ara-C, each in combination with...Read the original story

    Sep 30, 2016 | Leukemia

    Correspondence: Professor AK Burnett, Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 14XN, UK. E-mail: [email protected] Received 21 April 2016; Revised 14 June 2016; Accepted 12 July 2016 Accepted article preview online 2 September 2016; Advance online publication 30 September 2016 ara-C in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome .

    Comment?

  11. Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA...Read the original story w/Photo

    Oct 3, 2016 | Freshnews

    Jazz Pharmaceuticals plc today announced the initiation of a rolling submission of a New Drug Application to the United States Food and Drug Administration on September 30, 2016, seeking marketing approval of Vyxeos , an investigational agent for the treatment of acute myeloid leukemia . The company expects to complete the submission of the NDA by early 2017, and will request a priority review.

    Comment?

  12. Jazz Pharma Initiates Rolling NDA Submission For Vyxeos (CPX-351)...Read the original story

    Oct 2, 2016 | BioSpace

    The company expects to complete the submission of the NDA by early 2017, and will request a priority review. "Our initiation of the rolling NDA submission for Vyxeos brings us closer to an important goal of providing a new treatment option for patients with acute myeloid leukemia, a devastating and life-threatening disease," said ., Ph.D., global head of research and development and chief medical officer at Jazz Pharmaceuticals.

    Comment?

  13. The design of peptide-amphiphiles as functional ligands for liposomal ...Read the original story

    Aug 21, 2016 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Liposomal nanomedicine has led to clinically useful cancer therapeutics like Doxil and DaunoXome.

    Comment?

  14. With Impressive Data in Tow, Actinium Pharma An Overlooked Leader in New AML...Read the original story w/Photo

    Aug 10, 2016 | Freshnews

    Acute myeloid leukemia goes by many names, acute myelogenous leukemia and acute myeloblastic leukemia for example, and comes in eight different subtypes, making it unique from other forms of leukemia. Regardless of name or type, there's one common denominator; it's lethal.

    Comment?

  15. Aphios Receives Patent for SuperFluids CFL Drug Delivery ProcessRead the original story

    Dec 31, 1995 | Pharmaceutical Online

    The US Patent Office has granted Aphios Corp. Patent No. 5,776,486, titled "Method and Apparatus for Making Liposomes containing Hydrophobic Drugs."

    Comment?

  16. Cancer Drug Shortage Leads to Reliance on Chinese PlantRead the original story w/Photo

    Jul 25, 2016 | News Max

    Last September, U.S. regulators faced a dilemma: whether to allow importation of drug ingredients from a Chinese factory with a history of poor quality controls, or face shortages of treatments for American cancer patients. Six months earlier, visiting Food and Drug Administration inspectors had uncovered what the agency later called "broad data manipulation" at the factory, located in Taizhou, about 200 miles south of Shanghai.

    Comment?

  17. Facing cancer drug shortage, U.S. relies on banned Chinese factoryRead the original story w/Photo

    Jul 22, 2016 | Santa Cruz Sentinel

    Last September, U.S. regulators faced a dilemma: whether to allow importation of drug ingredients from a Chinese factory with a history of poor quality controls, or face shortages of treatments for American cancer patients. Six months earlier, visiting Food and Drug Administration inspectors had uncovered what the agency later called “broad data manipulation” at the factory, located in Taizhou, about 200 miles south of Shanghai.

    Comment?

  18. Facing Cancer Drug Shortage, U.S. Relies on Banned Chinese PlantRead the original story

    Jul 22, 2016 | The Washington Post

    Last September, U.S. regulators faced a dilemma: whether to allow importation of drug ingredients from a Chinese factory with a history of poor quality controls, or face shortages of treatments for American cancer patients. Six months earlier, visiting Food and Drug Administration inspectors had uncovered what the agency later called "broad data manipulation" at the factory, located in Taizhou, about 200 miles south of Shanghai.

    Comment?

  19. Why Celator Pharmaceuticals Is Up 1,610% in 2016Read the original story w/Photo

    Jun 27, 2016 | Fox News

    What: Shares of Celator Pharmaceuticals , a clinical-stageoncology-focused biopharmaceutical company, have rocketed 1,610% higher year to date,according to data from S&P Global Market Intelligence . Stellar data from a candidate aimed at an underserved population, and subsequent acquisition by Jazz Pharmaceuticals launched this biotech into orbit.

    Comment?

  20. Slingshot Insights Hosts Informative Call On Moleculin Biotech: Here Are The DetailsRead the original story w/Photo

    Jun 22, 2016 | Benzinga

    Slingshot Insights, a crowdfunded expert network that offers investment research tools, conducted an expert call on Moleculin Biotech Inc AML drug Annamycin last Friday. The goal of the call was to offer investors the opportunity to better understand how the drug differs from competing drugs, such as Celator Pharmaceuticals Inc 's VYXEOS.

    Comment?